Latest Breaking News On - Primary peritoneal - Page 1 : comparemela.com

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy Clinically. | June 4, 2023

United statesUniversity of oklahomaDavid omalleyKathleen moorePivekimab sunirineMirvetuximab soravtansineSarah cannon phasei programJames cancer centerUniversity of texas md anderson cancer centerAmerican society of clinical oncologyImmunogen incClinical researchOhio state universityDepartment of leukemiaClinical oncologyAnnual meeting

Immunogen (IMGN) Announces Presentation of Results from the Phase 3 MIRASOL Trial

Immunogen (IMGN) Announces Presentation of Results from the Phase 3 MIRASOL Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of oklahomaAnabel chanDavid omalleyRobert stanislaroMirvetuximab soravtansinePivekimab sunirineKathleen mooreAnna berkenblitCourtney okonekUniversity of texas md anderson cancer centerCompany annual report on formExchange commission onSarah cannon phasei programExchange commision onCompany quarterly report on form

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

WALTHAM, Mass. (BUSINESS WIRE) May 9, 2023

University of oklahomaUnited statesKathleen mooreAnna berkenblitCourtney okonekRobert stanislaroDavid omalleyMirvetuximab soravtansinePivekimab sunirineAnabel chanClinical researchExchange commissionDepartment of leukemiaImmunogen incJames cancer centerAmerican society of clinical oncology

Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers

/PRNewswire/ Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The.

United statesGreenfire bioZhen luRobert bastSteve morrisBajit gillWorld cancer research fund internationalUniversity of texas md anderson cancer centerAmerican cancer societyCancer centerScientific advisory boardClinical investigationAmerican cancerWorld cancer research fundClinical studyRecurrent ovarian

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer - read this article along with other careers information, tips and advice on BioSpace

Ashleyr robinsonKathleen mooreLaura benjaminUniversity of oklahomaLifesci partnersDrug administrationOncxerna therapeutics incXerna therapeuticsNavicixizumab plus paclitaxelPatients with platinum resistant ovarianPrimary peritonealFallopian tube cancerClinical oncologyChief executive officerOncxerna therapeuticsFast track